Insmed’s brensocatib: A candidate for bronchiectasis treatment, closer to approval

Insmed has been in the spotlight over the past few years for its pipeline agent, brensocatib, which has previously shown promising Phase II results, generating anticipation within the medical community ahead of the Phase III results for the treatment of bronchiectasis.